argenx SE American Depositary Shares (ARGX) fair value

ACCE thesis

argenx develops VYVGART, an FcRn-blocking antibody therapy used in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with additional indications in development across autoimmune disease. The moat is the drug's mechanism and the commercial infrastructure built around it, and the company's 59.3% revenue growth shows that the franchise is still ramping rather than maturing. Its 32.0% operating margin is high for a company still expanding its label count, and a forward P/E of 25.9 against a trailing 32.3 suggests the market expects earnings to keep compounding. The key question for a deeper look is how fast the pipeline indications can add to the existing base before competition from other FcRn and complement-pathway therapies erodes pricing. At a 53.2 billion dollar market cap with no index membership, the name sits outside the largest passive vehicles, which may matter for liquidity and for how the stock reprices on new data.